NO920476D0 - BENZIMIDAZOLES, PHARMACEUTICALS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION - Google Patents

BENZIMIDAZOLES, PHARMACEUTICALS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION

Info

Publication number
NO920476D0
NO920476D0 NO920476A NO920476A NO920476D0 NO 920476 D0 NO920476 D0 NO 920476D0 NO 920476 A NO920476 A NO 920476A NO 920476 A NO920476 A NO 920476A NO 920476 D0 NO920476 D0 NO 920476D0
Authority
NO
Norway
Prior art keywords
benzimidazolyl
alkyl
substd
opt
cooh
Prior art date
Application number
NO920476A
Other languages
Norwegian (no)
Other versions
NO301585B1 (en
NO920476L (en
Inventor
Norbert Hauel
Berthold Narr
Uwe Ries
Jacques Van Meel
Wolfgang Wienen
Michael Entzeroth
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO920476(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4103492A external-priority patent/DE4103492A1/en
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO920476D0 publication Critical patent/NO920476D0/en
Publication of NO920476L publication Critical patent/NO920476L/en
Publication of NO301585B1 publication Critical patent/NO301585B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Battery Electrode And Active Subsutance (AREA)

Abstract

1-Biphenylylmethyl-benzimidazole derivs. of formula (I) and their salts are new. (A) where: R1 = F, Cl, Br, 1-4C alkyl, cycloalkyl, CH2F, CHF2 or CF3 and is in the 4 position; R2 = R2 or may also be R2 when R4 = 1H-tetrazolyl; R'2 = 3-5C alkoxy substd. in the 3, 4 or 5 position by imidazolyl, or 2-5C alkoxy substd. in the 2, 3, 4 or 5 position by benzimidazolyl or tetrahydrobenzimidazolyl; R2 = e.g. (a) 2-(1-imadazolyl)ethoxy, 1-4C alkylsulphonyloxy, OSO2Ph or phenylalkylsulphonyloxy; (b) acylamino opt. N-substd. by 1-6C alkyl, Ph, cycloalkyl, phenylalkyl, cycloalkylalkyl, bicyclohexyl or biphenylyl, where acyl is 1-7C alkanoyl, 2-4C alkoxycarbonyl, 1-6C alkylsulphonyl, benzoyl, phenylsulphonyl, phenylalkylsulphonyl, naphthylsulphonyl, cycloalkylcarbonyl, phenylalkanoyl or cycloalkylalkanoyl, where phenyl rings are opt. substd. by 1-2 of F, Cl, Br, Me and OMe, or 3-oxopyridazylinyl or (l) 3-oxodihydropyridazinyl, opt. 2-substd. by alkyl or phenylalkyl and opt. further C-substd. by 1-2 alkyl gps., Het = a C- or imino-bonded 5-membered heteroaromatic ring or a C-bonded 6-membered heteroaromatic ring. (B) where: R1 = H or F, Cl, Br, 1-4C alkyl, CH2F, CHF2 or CF3 in the 5, 6 or 7 position; R2 = Het or a gp. as defined in (l) above; R3 and R4 are as defined in (A); provided that: (a) R2 is not 3-methylimidazo (4,5-b)pyridin-2-yl or 3-n-hexylimidazo(4,5-b) pyridin-2-yl in the 6 position when R1 = H, R3 = n-Pr and R4 = COOH; (b) R2 is not benzoxazol-2-yl in the 5 or 6 position when R1 = H, R3 = n-Pr or n-Bu and R4 = 1H-tetrazolyl; (c) R2 is not 1-methyl-2-benzimidazolyl in the 5 or 6 position or 1-n-butyl-2-benzimidazolyl, 1,5-dimethyl-2-benzimidazolyl or 1-methyl-5-trifluoromethyl -2-benzimidazolyl in the 6 postion when R1 = H, R3 = n-Pr and R4 = COOH; (d) R2 is not 1-methyl-2-benzimidazolyl in the 6 position when R1 = H, R3 = n-Bu and R4 = COOH or 1H-tetrazolyl; (e) R2 is not 2-benzimidazolyl in the 6 position when R1 = H, R3 = n-Bu and R4 = COOH; unless otherwise stated, alkanoyl, alkyl and alkoxy gps. are 1-3C and cycloalkyl gps. are 3-7C.
NO920476A 1991-02-06 1992-02-05 Benzimidazoles and drugs containing these NO301585B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4103492A DE4103492A1 (en) 1991-02-06 1991-02-06 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists
DE4117121A DE4117121A1 (en) 1991-02-06 1991-05-25 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists
DE4137812A DE4137812A1 (en) 1991-02-06 1991-11-16 New 1-(1,4-bi:phenyl-methyl) benzimidazole(s) as angiotensin II antagonists

Publications (3)

Publication Number Publication Date
NO920476D0 true NO920476D0 (en) 1992-02-05
NO920476L NO920476L (en) 1992-08-07
NO301585B1 NO301585B1 (en) 1997-11-17

Family

ID=27202166

Family Applications (3)

Application Number Title Priority Date Filing Date
NO920476A NO301585B1 (en) 1991-02-06 1992-02-05 Benzimidazoles and drugs containing these
NO2002011C NO2002011I2 (en) 1991-02-06 2002-10-21 Telmisartan + hydrochlorothiazide
NO2011005C NO2011005I1 (en) 1991-02-06 2011-05-03 Telmisartan optionally as a pharmaceutically acceptable salt and amlodipine optionally as a pharmaceutically acceptable salt and in particular Amlodipine besylate

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2002011C NO2002011I2 (en) 1991-02-06 2002-10-21 Telmisartan + hydrochlorothiazide
NO2011005C NO2011005I1 (en) 1991-02-06 2011-05-03 Telmisartan optionally as a pharmaceutically acceptable salt and amlodipine optionally as a pharmaceutically acceptable salt and in particular Amlodipine besylate

Country Status (26)

Country Link
EP (1) EP0502314B1 (en)
JP (1) JP2709225B2 (en)
AT (1) ATE166346T1 (en)
BG (1) BG62309B2 (en)
CA (1) CA2060624C (en)
CH (1) CH0502314H1 (en)
CZ (1) CZ287607B6 (en)
DE (2) DE59209330C5 (en)
DK (1) DK0502314T3 (en)
ES (1) ES2118095T4 (en)
FI (1) FI105547B (en)
HK (1) HK1011145A1 (en)
HR (1) HRP940752B1 (en)
HU (2) HU217084B (en)
IE (1) IE81111B1 (en)
IL (1) IL100864A (en)
LU (3) LU90372I2 (en)
MX (1) MX9200509A (en)
NL (2) NL990007I2 (en)
NO (3) NO301585B1 (en)
NZ (1) NZ241515A (en)
PL (1) PL169675B1 (en)
RU (1) RU2053229C1 (en)
SG (1) SG50481A1 (en)
SI (1) SI9210098B (en)
SK (1) SK279261B6 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224752A1 (en) * 1992-04-11 1994-02-03 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
DE4225756A1 (en) 1992-01-22 1994-03-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
DE4224133A1 (en) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
TW274551B (en) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4207904A1 (en) * 1992-03-12 1993-09-16 Thomae Gmbh Dr K SUBSTITUTED BENZIMIDAZOLYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5972990A (en) † 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
DE4315349A1 (en) * 1992-10-06 1994-11-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
JP3057471B2 (en) 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
DE4408497A1 (en) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K New bi:phenyl-methyl-benzimidazole derivs.
DK0853477T3 (en) * 1995-10-06 2003-02-10 Novartis Ag AT1 receptor antagonists for the prevention and treatment of postischemic renal failure and for the protection of ischemic kidneys
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
KR100572080B1 (en) * 1997-10-17 2006-04-17 유로진 리미티드 The use of inhibitors of the renin-angiotensin system
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
TR200805741T2 (en) * 1998-12-23 2008-10-21 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for the treatment of diseases caused by increased at-1 or at-2 receptors.
EP1013273A1 (en) * 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
PE20020617A1 (en) 2000-08-22 2002-08-05 Novartis Ag COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
DE10153737A1 (en) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DK1854454T3 (en) † 2002-01-16 2014-01-13 Boehringer Ingelheim Pharma Process for the preparation of amorphous telmisartan
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10335027A1 (en) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
DE10306179A1 (en) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Composition useful for preventing stroke comprises dipyridamole or its salt, acetyl salicylic acid and an angiotensin II antagonist
DE10314702A1 (en) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of telmisartan
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
DE10319592A1 (en) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of diabetic retinopathy with angiotensin II receptor blockers
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
KR20070061583A (en) * 2004-10-15 2007-06-13 테바 파마슈티컬 인더스트리즈 리미티드 Process for preparing telmisartan
KR101021828B1 (en) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 Benzene compound having 2 or more substituents
ITMI20050801A1 (en) * 2005-05-03 2006-11-04 Dipharma Spa PROCEDURE FOR THE PREPARATION OF TELMISARTAN
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
WO2007010558A1 (en) * 2005-07-19 2007-01-25 Matrix Laboratories Limited A process for the preparation of telmisartan
ES2246742B1 (en) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. USE OF A DERIVATIVE OF IMIDAZOLE.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1988091B1 (en) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
FR2916757B1 (en) * 2007-05-30 2009-07-17 Servier Lab NOVEL DIAZENIUMDIOLATE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
TWI406850B (en) * 2007-06-05 2013-09-01 Theravance Inc Dual-acting benzoimidazole antihypertensive agents
CN101743228B (en) * 2007-07-03 2014-01-29 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 Process for preparing telmisartan
CA2705921A1 (en) * 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivatives and their use as antihypertensive agents
CN102036937B (en) * 2008-03-20 2014-06-04 力奇制药公司 2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists
EP2103588A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
EP2103609A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
WO2009123483A1 (en) 2008-03-31 2009-10-08 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of telmisartan
EP2291177A2 (en) 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2123648A1 (en) 2008-05-20 2009-11-25 Chemo Ibérica, S.A. A process for the preparation of Telmisartan.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010004385A1 (en) * 2008-06-17 2010-01-14 Aurobindo Pharma Limited Process for the preparation of pure 4'-[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
EP2149566A1 (en) 2008-07-15 2010-02-03 Chemo Ibérica, S.A. A process for the preparation of telmisartan
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5559689B2 (en) 2008-08-06 2014-07-23 協和発酵キリン株式会社 Tricyclic compounds
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
PL2443094T3 (en) 2009-06-19 2013-08-30 Krka Tovarna Zdravil D D Novo Mesto Process for the preparation of telmisartan
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
EP2305650A1 (en) 2009-09-21 2011-04-06 Chemo Ibérica, S.A. Novel process for the preparation of telmisartan
CN101798300B (en) * 2010-02-23 2013-09-25 陈志龙 N-phenylindole methyl substituted bis-benzimidazole derivative and application thereof in reducing blood pressure and the like
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
AU2012303683B2 (en) 2011-08-26 2016-09-08 Wockhardt Limited Methods for treating cardiovascular disorders
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (en) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 Ultra-pure agonists of guanylate cyclase C, methods of making and using the same
CN109939113B (en) 2013-06-21 2022-02-15 恒翼生物医药科技(上海)有限公司 Bicyclic bromodomain inhibitors
EP3010917B1 (en) 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
JP5871294B1 (en) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Immediate release oral tablets
KR20170001921A (en) 2015-06-26 2017-01-05 대원제약주식회사 A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof
KR20170012703A (en) 2015-07-22 2017-02-03 대원제약주식회사 A pharmaceutical composition comprising telmisartan and a preparation method thereof
JP6411662B2 (en) 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fixed volume formulation
KR101872726B1 (en) 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
US10905676B2 (en) 2017-07-07 2021-02-02 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
US11401264B2 (en) * 2018-03-30 2022-08-02 Orizuru Therapeutics, Inc. Heterocyclic compound
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
CA3233464A1 (en) * 2021-10-04 2023-04-13 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (en) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K BENZIMIDAZOLE, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU1836357C (en) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine

Also Published As

Publication number Publication date
CZ287607B6 (en) 2001-01-17
ATE166346T1 (en) 1998-06-15
DE10299029I1 (en) 2003-01-23
SK279261B6 (en) 1998-08-05
SI9210098A (en) 1994-12-31
EP0502314B1 (en) 1998-05-20
HU9200355D0 (en) 1992-04-28
CS30692A3 (en) 1992-08-12
JP2709225B2 (en) 1998-02-04
HU211524A9 (en) 1995-11-28
DE10299029I2 (en) 2006-06-29
NL300095I2 (en) 2002-11-01
SI9210098B (en) 2000-06-30
LU90950I2 (en) 2002-10-30
PL169675B1 (en) 1996-08-30
DE59209330C5 (en) 2013-10-31
AU1070792A (en) 1992-08-13
NZ241515A (en) 1994-10-26
ES2118095T4 (en) 2011-04-07
LU91802I2 (en) 2011-05-30
CA2060624A1 (en) 1992-08-07
FI105547B (en) 2000-09-15
CH0502314H1 (en) 2012-03-15
PL293387A1 (en) 1993-01-25
MX9200509A (en) 1992-08-01
FI920486A (en) 1992-08-07
RU2053229C1 (en) 1996-01-27
NO301585B1 (en) 1997-11-17
DE59209330D1 (en) 1998-06-25
NL990007I1 (en) 1999-06-01
EP0502314A1 (en) 1992-09-09
NL300095I1 (en) 2002-09-02
IE920373A1 (en) 1992-08-12
AU655794B2 (en) 1995-01-12
IL100864A0 (en) 1992-11-15
HU217084B (en) 1999-11-29
NO920476L (en) 1992-08-07
IL100864A (en) 1996-01-19
NO2011005I1 (en) 2011-05-16
LU90372I2 (en) 1999-05-12
BG62309B2 (en) 1999-07-30
JPH04346978A (en) 1992-12-02
NO2002011I2 (en) 2008-03-03
HK1011145A1 (en) 1999-07-02
FI920486A0 (en) 1992-02-05
SG50481A1 (en) 1998-07-20
HRP940752A2 (en) 1997-04-30
ES2118095T3 (en) 1998-09-16
CA2060624C (en) 1999-12-21
IE81111B1 (en) 2000-03-08
HRP940752B1 (en) 2001-02-28
DK0502314T3 (en) 1999-03-29
NL990007I2 (en) 1999-07-01
HUT60493A (en) 1992-09-28

Similar Documents

Publication Publication Date Title
NO920476L (en) BENZIMIDAZOLES, PHARMACEUTICALS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION
GB1088531A (en) Substituted benzamides
MY100665A (en) 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives.
IE34765B1 (en) Nitrofuryl-thienopyrimidines
CA2016181A1 (en) Arylthiazolylimidazoles as 5ht3 antagonists
DE3664912D1 (en) 5-(azolyloxyphenylcarbamoyl)-barbituric acid derivatives as active agents in anthelmics
KR890005054A (en) 4-aryl-5-carbamoyl-1, 4-dihydropyridine useful as therapeutic agent
EP0237289A3 (en) Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
CS743389A3 (en) Amino(methyl)phenyl derivatives, process for their preparation and use
AU576269B2 (en) Heterocyclic histamine h2-receptor antagonists
HUP0105406A2 (en) Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
SE8107524L (en) Heterocyclic Associations
ES429864A1 (en) 1,4-Dihydro-4-oxo-pyridylacetamido cephalosporins and their utilization as medicinal agents for combating bacterial infections
FI921298A (en) Process for the preparation of a 5- (6-imidazo / 1,2-a / pyridyl) pyridine derivative useful as a drug
IT1230754B (en) New 1-heterocyclyl-2-amino-ethanol cpds.
IT1217657B (en) New 1-heterocyclyl-2-amino-ethanol cpds.

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TELMITARSAN; NAT. REG. NO/DATE: NO , EU/1/02/21 20020510; FIRST REG. NO/DATE: EP , EU/1/02/21 20020419

Spc suppl protection certif: 2002011

Filing date: 20021021

Extension date: 20170205

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TWYNSTA; NAT. REG. NO/DATE: EU/1/10/648/1-28/NO 20101129; FIRST REG. NO/DATE: EU , EU/1/10/648/001-028 20101007

Spc suppl protection certif: 2011005

Filing date: 20110503

MK1K Patent expired
LC4 Limitation of patent rights - b3 (par. 39b patent act)

Effective date: 19971117

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2011005

Effective date: 20131211